Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of NFC-1 in children with ADHD
NCT03006367Phase 1Completed
- Sponsor
- Avalo Therapeutics
- Start
- Jan 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fasoracetam in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by Avalo Therapeutics. Primary endpoints: Area under the plasma drug concentration-time curve (AUC0-24h), Area under the plasma drug concentration-time curve (AUC0-inf) at 28 hours and 7 more. Started Jan 2017; status: completed.
02
Drugs
fasoracetam
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03006367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006367.